Tag:

Ono Pharmaceutical

Latest Headlines

Latest Headlines

Anti-PD-1 cancer star nivolumab wins world's first regulatory approval

The anti-PD-1 immuno-oncology drug star nivolumab has won the race to the world's first regulatory checkered flag for an approval. Ono Pharmaceutical, which picked up the Japanese rights to the drug in a collaboration deal with Medarex back in 2005, says regulators in the Asian country approved nivolumab for sale as a treatment for unresectable melanoma.

Merck KGaA pulls the plug on Ono's MS drug as the market crowds

Merck KGaA is backing out of its multiple sclerosis deal with Japan's Ono Pharmaceutical, deciding not to take the plunge on Phase III development for a drug that would face stiff competition.

Top 10 experimental cancer drugs- 2013

In our third annual report on 10 exciting cancer drugs, there are plenty of R&D programs zipping through trials with the blessing of the FDA, which has awarded "breakthrough" status for expedited development to treatments in oncology more than any other field. Read the report >>

AMRI inks 5-year CDMO deal with Ono

AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.

Ono's oral MS drug eliminates brain lesions in promising PhII study

An oral MS drug was credited with eliminating a large percentage of the brain lesions characteristic of the disease.

UPDATED: Merck KGaA bolsters MS pipeline in $20M pact with Ono

If at first you don't succeed with a blockbuster drug, try, try again. Merck KGaA 's Serono division has worked out a pair of new deals that will bring its R&D division in league with the

KAI banks $13M in development deal with Japan's Ono

South San Francisco-based KAI Pharmaceuticals has inked a Japanese development and marketing deal for its lead therapy, nabbing a $13 million upfront payment from Ono Pharmaceutical. Now nearing the

Onyx snags $339M Japan deal for PhIII cancer med

Onyx's $851 million deal to buy out Proteolix and its potential blockbuster cancer drug is returning some handsome rewards this morning. Ono Pharmaceutical snagged the Japanese rights to the